Company Overview
| Stock Name | Orbusneich |
|---|---|
| Stock Code | 06929 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 一家專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商,亦專攻冠狀動脈支架產品,並積極擴展至神經血管介入及結構性心臟病領域。 |
| Listing Date | 2022-12-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港新界沙田香港科學園20E號樓3樓303室和305室 |
| Business Address (Hong Kong) | 香港新界沙田香港科學園20E號樓3樓303室和305室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | orbusneich.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 8.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 4,400 |
| Par Value | To be extracted |
| Offer Period | 2022-12-13 to 2022-12-16 |
| Global Offering Shares | 54,633,000 shares |
| HK Public Offer Shares (Initial) | 5,464,000 shares (10.0%) |
| Public Offer Lots (Initial) | 10,928lots (Pool A5,464lots,Pool B5,464lots) |
| International Placing Shares (Initial) | 49,169,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 827,769,937 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 65.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 480,770,400 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 4,400 |
| 2 lots | 1,000 | HK$ 8,800 |
| 3 lots | 1,500 | HK$ 13,200 |
| 4 lots | 2,000 | HK$ 17,600 |
| 5 lots | 2,500 | HK$ 22,000 |
| 6 lots | 3,000 | HK$ 26,400 |
| 7 lots | 3,500 | HK$ 30,800 |
| 8 lots | 4,000 | HK$ 35,200 |
| 9 lots | 4,500 | HK$ 39,600 |
| 10 lots | 5,000 | HK$ 44,000 |
| 12 lots | 6,000 | HK$ 52,800 |
| 14 lots | 7,000 | HK$ 61,600 |
| 16 lots | 8,000 | HK$ 70,400 |
| 18 lots | 9,000 | HK$ 79,200 |
| 20 lots | 10,000 | HK$ 88,000 |
| 30 lots | 15,000 | HK$ 132,000 |
| 40 lots | 20,000 | HK$ 176,000 |
| 50 lots | 25,000 | HK$ 220,000 |
| 60 lots | 30,000 | HK$ 264,000 |
| 70 lots | 35,000 | HK$ 308,000 |
| 80 lots | 40,000 | HK$ 352,000 |
| 90 lots | 45,000 | HK$ 396,000 |
| 100 lots | 50,000 | HK$ 440,000 |
| 120 lots | 60,000 | HK$ 528,000 |
| 140 lots | 70,000 | HK$ 616,000 |
| 160 lots | 80,000 | HK$ 704,000 |
| 180 lots | 90,000 | HK$ 792,000 |
| 200 lots | 100,000 | HK$ 880,000 |
| 400 lots | 200,000 | HK$ 1,760,000 |
| 500 lots | 250,000 | HK$ 2,200,000 |
| 800 lots | 400,000 | HK$ 3,520,000 |
| 1,000 lots | 500,000 | HK$ 4,400,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,200 lots | 600,000 | HK$ 5,280,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 3.17B |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +205% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,284,375,446 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損約4.4百萬美元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 113,970,400 |
| Listing Expenses / Funds Raised | ~23.71% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue | 96,342 | 88,472 | 116,462 |
| Cost of sales | -30,895 | -30,452 | -35,290 |
| Gross profit | 65,447 | 58,020 | 81,172 |
| Other income and gains, net | 1,500 | 3,310 | 365 |
| Selling and distribution expenses | -32,251 | -15,707 | -26,694 |
| Administrative expenses | -19,958 | -14,654 | -8,187 |
| Operating profit | 7,989 | 8,694 | 19,440 |
| Net finance costs | -482 | -1,393 | -5,595 |
| Share of associates and JVs | 0 | 0 | -46 |
| Profit before tax | 7,507 | 7,255 | -1,318 |
| Income tax expense | -549 | -184 | -3,126 |
| Profit for the year | 6,958 | 7,071 | -4,444 |
| Profit attributable to owners | 6,958 | 7,071 | -4,444 |
Balance Sheet
| Item | 2019 | 2020 | 2021 | 2022-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 13,631 | 15,112 | 175,886 | |
| Trade and bills receivables | 21,515 | 29,179 | 33,172 | |
| Inventories | 976 | 275 | 927 | |
| Total current assets | 74,177 | 74,467 | 235,355 | |
| Total assets | 95,692 | 103,646 | 268,527 | |
| Total current liabilities | 144,681 | 55,466 | 16,450 | |
| Total liabilities | 247,983 | 68,750 | 85,415 | |
| Total equity | -152,291 | 34,896 | 183,112 | |
| Equity attributable to owners | -152,291 | 34,896 | 183,112 | |
| Interest-bearing borrowings | 38,462 | 39,898 | 0 | 0 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021 | 2022-06 |
|---|---|---|---|---|
| Net cash from operating activities | 1,590 | 12,666 | 20,498 | |
| Net cash from investing activities | -3,053 | -11,245 | -5,219 | |
| Net cash from financing activities | 163,050 | 36,000 | -58,384 | |
| Net increase in cash | 161,587 | 37,421 | -43,105 | |
| Purchase of PP&E | -2,732 | -943 | -1,247 | -935 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 9.15 |
|---|---|
| First Day Open | HK$ 8.8 |
| First Day Change | 3.98% |
| First Day Volume | 4592500.0 |
| First Day Turnover | 40174300.0 |
| Use of Proceeds | 1、30.0%(或約110.0百萬港元)分配予在研產品開發及商業化;
2、54.2%(或約198.8百萬港元)被分配用于擴大我們的產能;
3、10.8%(或約39.7百萬港元)用于為潛在戰略收購、建立戰略合作伙伴關系及其他業務發展提供資金;
4、5.0%(或約18.3百萬港元)用作營運資金及用于其他一般企業事項。 |
Underwriting Syndicate
Overall Coordinators (5)
Joint Bookrunners (8)
Joint Lead Managers (8)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 杭州富阳产业基金投资管理有限公司 | 313,997,200 HKD | — | 65.31% | — | 6 months | 2023-06-23 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 錢永勛 | — |
| Company Secretary | 陳泳成 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | HART持有本公司63.00%已發行股本,錢永勛先生及劉桂禎女士分別持有HART 55%及45%股權;深圳市創新投資集團有限公司持有11.84%。 |
|---|




